OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-03-31-accounts

Company no. 01902326 Charity no. 291714

Bristol Drugs Project Limited Report and Audited Financial Statements 31 March 2024

Bristol Drugs Project Limited

Contents

For the year ended 31 March 2024 For the year ended 31 March 2024 For the year ended 31 March 2024
Page
Reference and administrative details 1 - 2
Chair's statement 3 - 4
Trustees' report 5 - 26
27 - 30
Statement of financial activities 31
Balance sheet 32
Statement of cash flows 33
Notes to the financial statements 34 - 55

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31 March 2024

Company number 01902326 Charity number 291714 Registered office and 11 Brunswick Square operational address Bristol BS2 8PE Tel: 0117 987 6000 Trustees The trustees who served during the year and up to the date of this report were as follows: K Barker D Bradnock K Curling P Godfrey G Henderson appointed 15 January 2024 M Lea, BA Hons, FCA, CTA J Long QPM, BA Hons, MA (Chair) R Mayall R Paine T Rice J Risk T Smyth MRCGP FRCS M Wilkinson Senior management team Anna Smith, Chief Executive Officer (appointed 3 July 2023) Benjamin Judd, Director of Business Development (appointed 3 July 2023) Rachel Ayres, Business Development Support Manager (resigned 5 May 2023) Lydia Plant, Director of Operations Kathryn Talboys, Service Manager (resigned 30 June 2024) Shoba Ram, Service Manager (resigned 28 June 2023) Karen Black, Interim Management Support Bankers Unity Trust Bank plc Triodos Bank Nine Brindleyplace Deanery Road 4 Oozells Square Bristol Birmingham BS1 5AS B1 2HB Cambridge & Counties Bank Charnwood Court 5B New Walk Leicester LE1 6TE

1

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31 March 2024

Solicitors Gregg Latchams Ltd 7 Queen Square Bristol BS1 4JE Investment managers Cazenove Capital Schroder & Co. Limited 1 London Wall Place London EC2Y 5AU Auditors Godfrey Wilson Limited Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

2

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice - Accounting and Reporting by Charities (effective from January 2019).

Bristol Drugs Project Limited (BDP) is able to report on a broadly successful year for the Charity during 2023/2024, which is additionally characterised by work and preparation in advance of a significant year of the recommissioning of drug and alcohol services for 2025. Our progress has been tenaciously led by Anna Smith who was appointed as our new CEO in July 2023. This followed the sad loss of our former CEO and cocontinues its important mission and the commitment and hard work of all the staff and volunteers has meant BDP continues to deliver high quality services to people in Bristol.

Bristol is justifiably recognised as a leading proponent of shared care work in drug and alcohol services. to be central to our efforts during 2023/24. We have been successful in maintaining and further developing a highly skilled workforce to deliver this and, despite current challenges presented by the ts capabilities through equality, diversity and inclusion (EDI) initiatives and has been fortunate in being able to have support from Stand Against Racism & Inequality (SARI), a renowned local agency in this field, in doing this. This has covered recruitment, training and enhanced community engagement at all and draw from the good ideas of staff and volunteers.

Alongside its mainstream commissioned services, BDP has continued to encourage its service users to engage with a range of creative, therapeutic and individually fulfilling activities. These include support for particular needs groups, a successful choir and various celebratory events. For example, recently BDP was also again successful in securing a grant from the National Lottery Community Fund for its allotment project, illustrative of the local community activities which we promote in support of our contracted services.

Whilst maintaining a strong focus on delivering existing services, the Charity has embraced new opportunities to develop and transform programmes of work with its partners. For example, Bristol City Council has augmented its current Drug and Alcohol Strategy for Bristol with a transformation programme to which BDP is making a significant contribution. This comes with additional funding for eighteen new staff, enabling the introduction of teams for drugs and alcohol assessment and an Implementation Manager. Importantly, the programme seeks to reduce the caseloads for shared care. BDP has also entered a partnership with The Loop to carry out drug checking locally. There is substantial evidence that drug strength checking reduces related harms. BDP is working with its partners to capitalise upon this and use resulting information to improve health awareness responses across the City. Through these initiatives BDP also maintains its proud ethos of being a learning organisation.

As previously mentioned, Bristol will see a major re-commissioning of drug and alcohol services during 2024, for implementation in 2025, when current contracts end. During this reporting period, BDP has engaged with prospective partners and undertaken considerable work in preparing bids for these commissioned services. These efforts come with a number of additional opportunities and legal costs made provision from reserves to ensure the Charity is well placed to enter the tendering phase and by the end of July 2024. Added to events following a general election, the year ahead is likely to herald

3

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

significant change for organisations and charities operating in the drug and alcohol sector. BDP is preparing in anticipation of this.

The accounts for the year ending 31 March 2024, show that BDP made provision from reserves of £85,867 to delivery and/or to cover reduced income. However, prudent management and variations in staff posts and costs have contributed to a year end surplus of £69,010. This includes an additional return from reserves invested. Currently, the Board of Trustees has not seen need to make provision from reserves to the budget for the year ahead but remains in a position to be able to do so if necessary, which will allow the Charity to meet its contractual commitments with certainty until new contracts are awarded following re-commissioning.

Henderson. Some improvements have been made to its governance structure and committees however, to allow the Board to meet ever-changing circumstances and the demands faced from growth in recent years. The Board has also received EDI training and there are plans to develop trustee recruitment. I am grateful to all our current trustees for their continued commitment and wisdom, during another challenging year for the Charity. The trustees remain a full, committed and broadly experienced ults of the re-commissioning of services and political change. On behalf of the Board, I extend thanks also to Anna Smith and her senior team for its immense hard work leading BDP through this reporting period.

Most importantly, I also wish to thank all the staff and volunteers at BDP whose daily, truly significant and challenging work, in the midst of change, has led to another year of achievement and a growing future potential to provide ever higher quality services to people who need them.

John Long QPM

Chair of Trustees

4

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

The Board of Trustees present their annual report and financial statements for the year ended 31 March This is an important document, which summarises Br highlights key achievements; and identifies challenges and ambitions for 2024/25.

OBJECTIVES AND ACTIVITIES

Bristol Drugs Project s (BDP) charitable purpose is described in the objects within the Charity s Memorandum and Articles of Association as:

Achievements & Performance Delivering Public Benefit

This report describes how the charity ivities fulfil the Public Benefit provisions of the Charities Act 2011. In doing this, the charity has complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission. The Board of Trustees is satisfied that BDP has charitable aims that are carried out for public benefit, specifically:

This report describes s activities transparently, documenting their relevance to our objects as a Charity and demonstrating that s activities are effective in achieving the Charity s aims. BDP has reviewed any potential negative impact of its activities to satisfy itself that the benefits far outweigh any detriment or harm arising from the Charity activities. For example, BDP takes active steps to minimise any potential harm arising from its Needle and Syringe Program by placing emphasis on safe disposal of injecting equipment supplied by BDP in order to minimise the risks that can arise from inappropriate disposal.

Who We Provide Public Benefit For

delivers services to individuals, families, and communities affected by drug, alcohol or other addiction, which reduce harm, maximise individuals potential and promote independence from drugs and alcohol

How We Provide Public Benefit

10 March 2024 marked thirty-eight years of providing effective services to people with alcohol or drug problems, designed to reduce harm, maximise individuals potential and promote independence from drugs and alcohol.

We continued to provide a wide range of interventions for people experiencing problems with alcohol or drugs, of all ages, at all stages of the complex process of behavioural change. The services we provide are person-centred and tailored to individual need and choice - not dictated building their recovery capital (rewarding relationships, valued activity, adequate housing, and

5

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

income). We aim to be supporting not judging; recognising the impact of Adverse Childhood Experiences with trauma-informed approaches; nurturing change with passion and ambition; and enabling people to acquire skills and self-belief, which makes recovery an enduring and rewarding reality.

At one end of the spectrum of change, we deliver services intended to reduce the harms associated with drug and alcohol use. For example, our Needle and Syringe Program, Naloxone supply to reduce fatal overdose, and a Physical Healthcare service - provided in collaboration with local GPs BrisDoc - to enable skin and soft tissue infections and other healthcare needs to be tackled early to reduce the risk of hospitalisation and harm.

At the other end of that spectrum, we deliver services which reconnect individuals with their family, community and life opportunities, as well as supporting them to maintain their chosen changes to drug and alcohol use, whether that is abstinence or more controlled use with reduced harm.

All of the C delivery. They are provided at multiple locations, including thirty-eight GP surgeries, youth and family centres, and through extensive outreach to ensure easy access for those that require different approaches. Our Mobile Harm Reduction Service vehicle, our premises at Brunswick Court and our partner premises are compliant with the building provisions of the Disability Discrimination Act.

Our People and Equality, Diversity and Inclusion

Services were delivered by a total of 93 staff across the year, with an average of 78 Full Time Equivalents. Our staff team grew significantly in quarters three and four thanks to additional eighteen staff, funded to 31 March 2025, offering a range of enhanced services designed to make

Our volunteer support team provided a total of 2,308 hours of valuable support to our front-line services within the year. This represents an avoided cost of £9,971. More importantly, these hours represent BDP equipping its volunteers with skills, a passion for harm reduction, ambassadorship and

In quarter 4 BDP completed the first part of our re-accreditation under the Investing in Volunteers scheme. Investing in Volunteers (IiV) is the UK quality standard for good practice in volunteer management. This represents both a material and values-based commitment by BDP showing how embedded and enga -assessment with no concerns recorded, we are confident this will be achieved and ratified in Q1/Q2 2024/5.

looks to recruit from under-represented communities creating employment opportunities for those who are economically inactive. During 23/24 we supported five trainees by providing full-time work and supporting them through a recognised Health and Social Care qualification, funded by local businesses through the apprenticeship levy, at no cost to BDP. We are delighted to report that all five of our trainees have secured permanent employment across a range of roles at BDP.

We have put considerable effort into becoming a continual learning organisation around equality diversity and inclusion (EDI) this year, setting up an internal cross-organisational working group facilitated by Temba Mahari from Stand Against Racist Incidents (SARI), whom we contract as an expert consultant to support this work.

6

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

The group has decided to focus first on our response to increasing diversity in the area of racial diversity as it is an area we are under-represented in across all levels of the organisation, when compared to our local community.

This represents our commitment to change and has manifested itself in an EDI survey, which we undertook in autumn 2023 to set a baseline of evidence. We will repeat the survey in June 2024, as we have had a significant intake of new staff and will continue to measure our representation to use it to focus energy to represent groups.

Our initial ED&I survey has provided a range of insights into our staff demographics:

Age Range of BDP Staff as at Q3 23/24

The group has looked at how we might recruit staff and volunteers from under represented racial groups by developing relationships with grass roots community centres so they understand our work and will post and display our vacancies. This group will continue throughout the year and has begun a way of thinking and bringing about ideas, which we intend to action.

7

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

Ethnicity of BDP staff as at Q3 23/24

A spin-off from this group has been a Reading Group with representatives across the organisation, who are studying How to Be An Anti-Racist, by Ibram X. Kendi, coming together every 6 weeks with a facilitator, to discuss 2-3 chapters. This is intended to raise our awareness as a staff team about action we could take to improve our anti-racist response. Our board has also had training in EDI and has committed to recruiting two board members who are EDI representatives and we are working with SARI to achieve this through their networks. We have committed to having EDI training on a rolling programme for all staff as a mandatory part of our induction programme.

Sexual Orientation of BDP staff as at Q3 23/24

Partnerships

BDP continues to operate as an effective partner to both statutory and non-statutory organisations and services at a national, regional and local level.

BDP was commended by regional leaders at the Office for Health Improvements and Disparities (OHID) for the quality of its communications in response to high numbers of drug overdoses in the summer of 2023, following the introduction of Nitazenes into the illicit drug supply chain. BDP literature and information was shared widely with commissioners and service providers across the south-west as a model for providing an effective response to minimise the risks of fatal and non-fatal overdoses.

8

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

-checking service regularly, from

January 2024. With the service hosted by BDP at 11 Brunswick Square on the last Saturday of each month, individuals can submit substances of concern for analysis and they will be directly informed if the substance they submitted poses significant risk to themselves or others.

(BCC) Public Health Team and ROADS Wiltshire Mental Health Partnership NHS Trust (AWP). Our mature ROADS partnership with AWP continues and included sub-contracted de release from prison and the Complex Prescribing service within ROADS.

-year drug strategy, BDP played a central role in the rapid rollstrategic objectives for the ROADS system. These new services have resulted in an extended subcontract arrangement between BDP and AWP as well as the secondment of two staff from DHI to BDP.

with Dentaid and Brisdoc in order to provide a number of emergency dental session via the mobile Dentaid Truck, to service users who would otherwise be unable to access the treatment that they need.

thirtycommunities across Bristol whilst additionally improving access to primary care interventions for people who use drugs and alcohol. Links with GP practices have been further strengthened by i) the into treatment far easier, ii) the provision of a strengthened assessment team for GP-referred clients, and iii) increased BDP staffing numbers within the Shared Care team.

BDP continued to work closely with partners as part of the Keeping Bristol Safe Partnership (KBSP) Bristol Secondary Schools, homelessness pathway housing providers, and a wide range of other voluntary and community sector providers in order to ensure delivery of effective services.

Our partnership with Bournemouth Symphony Orchestra continues to go from strength to strength, enabling our Recovery Orchestra to put on a number of excellent performances including its Spring Show attended by former Bristol West MP and Shadow Secretary of State for Digital, Culture, Media and Sport, Thangam Debbonaire

public performances and collaborations with the Recovery Orchestra.

Profile & Influence

In order to announce the arrival of Anna Smith (CEO) and a restructured Senior Leadership Team, BDP secured a double-page article in sector magazine Drink and Drugs News, which stressed the importance of place-based services and local expertise in the delivery of community drug and alcohol services. With other locality-based services merging with larger providers and rebranding accordingly, BDP represents one of the last of its kind and continues to exert influence on the sector disproportionately to its size. In the run up to recommissioning, BDP used the article to position itself as essential to a successful Bristol treatment system.

-checking service received National attention and highOperations, Lydia Plant conducting multiple interviews including with BBC Breakfast.

9

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

include:

BDP was commended by OHID at a regional level for the quality of its response to an increased number of fatal and non-fatal overdoses in Bristol following the introduction of Nitazenes into the local illicit drug -practice example in order to support commissioners and treatment providers to develop their own communications in order to reduce harm within their own communities.

BDP was asked to meet Yvette Cooper, Shadow Home Secretary for a round-table discussion with community organisations working with young people about the realities of knife crime. There have been four tragic deaths of young men in Bristol since Christmas 2023. A member of our Targeted Youth Support Team, accompanied Anna Smith, CEO, to this intimate meeting.

BDP continued to be represented at the National Workforce Development Working Group coordinated by Collective Voice Network.

Research partnerships:

Supporting academic research and continuing to contribute to the evidence base around substance use has continued to be a focus for BDP in the last 12 months. We entered Phase 2 of a three-year long research project with the London School of Hygiene and Tropical Medicine of SIPP Safe Inhalation Pipe Provision used as an intervention to reduce health harms and enhance service engagement among people who use Crack Cocaine in England. This year, with a special dispensation from Avon and Somerset Police, we distributed over 1,800 pipes to over 1,000 individuals, followed by another behaviour change survey, including around 100 people who have never made contact with a drug and alcohol treatment service in their lifetime.

BDP and the University of Bristol recruited and interviewed people experiencing homelessness to contribute to ongoing research assessing how services can best respond to a changing climate. With an acknowledgement that services currently have mechanisms for low temperatures, we contributed to research into how services could better respond to extreme heat and extreme wet weather.

A member of staff and several service users have been a part of "Nothing about us, without us", a collaboration with the University of Bristol to understand people's experiences of stigma in the context of collecting opiate substitution therapy (OST) medication from their pharmacy. We have taken part in a variety of co-produced workshops and are now working towards a set of recommendations for pharmacies.

BDP are a key contributor to the unlinked anonymous monitoring (UAM) surveys of people who inject drugs (PWID). This aims to measure the level of HIV, hepatitis B and hepatitis C in this population by taking anonymised blood samples. They also monitor the levels of risk and protective behaviours in this population. The surveys provide data on people who inject psychoactive drugs (such as heroin) and also on people who inject image and performance enhancing drugs (IPEDs). This year, we completed surveys with 70 individuals.

10

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

We continue to regularly engage with a range of researchers and look forward to growing these relationships in the coming year.

For adults, our range of services included:

Our open access Advice Centre in central Bristol remained open Monday to Friday and Saturday mornings. Services provided include triage and referral for a ROADS assessment; support in accessing other statutory and non-statutory services; and a safe, non-judgmental space with respite including tea and coffee! - from often harsh day-to-day lives, including homelessness.

Harm reduction initiatives included:

launching new services -related deaths, raise the number of people in treatment and improve the quality of treatment for alcohol users in the city:

Our Nursing Service, staffed through our partnership with BrisDoc, continued to provide a suite of physical healthcare interventions through open-access services at BDP and through Outreach and Inreach to people who find it hard to access primary care nursing services.

A telephone helpline (5 days per week) for advice, support and information and an email support facility for those who prefer not to use the phone or want a more discrete service.

Our lively and popular weekly women only session with crèche facilities continued.

Our 50+ Group which provides older people the opportunity to give and get support from their peers continued and extended in the year to meet increasing demand with a second weekly group on Friday and monthly Saturday morning gathering.

11

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

Our established LGBTQ+ group, Prism, continued to meet weekly with a format of three therapeutic groups followed by a social group with content designed by participants.

Over the past year, club and festival harm reduction service, The Drop, has continued to embed harm reduction within Night Time Economy (NTE) by:

Our Opioid Assisted Treatment Programme (OAT) remains the largest programme in the UK, delivered in partnership with all but one P Practices. This makes it a genuine placebased service offering easy access in the heart of communities across Bristol whilst also improving access to primary healthcare services for people who use drugs. Services provided by the Shared Care service reduce harm and the risk of opiate overdose and can provide a fully supported community detoxification programme with referrals to specialist prescribing via ROADS partners, if the client has additional complex needs.

Our Link Worker roles create identity-based pathways into treatment. These staff engage directly with the public and support other organisations to identify people who could benefit from drug or alcohol treatment and are not finding their way to us. They deliver brief interventions and support engagement with treatment, plus ensuring that services and communities have contemporary information about link workers roles focus on diverse communities, people with mental ill health or learning disability and people engaged with families in focus, people suffering domestic violence and abuse and improving access to respiratory & renal health services.

Thanks to additional funding from BCC, we were able to hold 36 Bristol Recovery Orchestra rehearsals, 50 Rising Voices Choir rehearsals, and 3 Creative Communities joint concerts.

In 2023/24 Creative Communities also:

Sober Spaces continued to host monthly Open Mic nights, facilitated by BDP staff, volunteers and service users. They also held their first Sober Rave at Basement 45 which proved a hugely successful sell-out event.

spoken word and poetry group, held their first performance, featuring art created and delivered by BDP staff and service users.

Benefits for individuals

3,199 individual adults benefited from s structured treatment services during 2023/24.

12

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

271 individuals used our Needle and Syringe Programme only. 4 people were injecting Image or Performance Enhancing Drugs

A further 422 individuals are estimated to have accessed our Needle and Syringe Program based in 20 pharmacies across the city, interacting with the service an estimated 5,781 times.

76% (2,425 individuals) of the people BDP supported during this year were 25-54 years of age.

15% (480 individuals) of the people BDP supported during this year were aged 55 or older.

28% (898 individuals) of the people BDP supported during this year were female.

5% (159 individuals) of the people BDP supported during this year were from Black, Asian or Minority Ethnic communities.

5% (147 individuals) of the people BDP supported during this year were of mixed heritage.

4% (143 individuals) of the people BDP supported during this year were from other White European communities.

5% (169 individuals) of the people BDP supported during this year, English was not their first language . 46 community languages in addition to English were spoken.

8% (267 individuals) of the people BDP supported during this year identified as Lesbian, Gay, Bisexual, Transgender or questioning.

29% (923 individuals) of the people BDP supported during this year described themselves as having a disability.

54% (1,714 individuals) of those who disclosed their religion (2,602 individuals) reported having .

Heroin remains the most widely used main drug by 59% (1,901 individuals) of all those BDP supported during this year; however poly drug use, with heroin and crack cocaine used in combination, remains the most common pattern of usage, with 63% (1,196 individuals) of people using heroin also using crack cocaine.

8% (243 people) who benefited from BDP services are living with children.

20% (654 individuals) of the people BDP supported during this year were in regular employment.

People living in all areas of Bristol benefitted from services with the largest populations living in eight wards:

13

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

For children and young people, our range of services included:

The service works preventatively to support young people from moving into more serious drug use and as part of a wider whole family approach, below are some examples of our reach throughout 2023/24:

BDP continue to deliver targeted services in Bristol for young people who are both using substances themselves and / or affected by parental substance use. The interventions are up to 12 weeks duration with children and young people aged 11-19 years (up to 24 weeks with learning difficulty or disability). During 2023/34 the team engaged with 161 who were using substances themselves and 69 who , 83% reporting a positive outcome following the intervention. The team also made 54 referrals into more structured treatment.

use, continues to work with 5-16 year olds (split into two age groups). During 2023/34 the team support 48 Children and Young People , delivering 33 groups .

opportunity to have a personal, confidential education session with a BDP Youth Worker as an alternative to receiving a warning or caution, with the choice to then be referred into services for further support. Referrals are received each week from Avon & Somerset Constabulary, most for possession of cannabis, with a small number for possession of ketamine, crack and heroin. During 2023/24 we assessed 38 young people and made 12 referrals into CYP support services.

Our New Leaf project continues to serve young people with entrenched cannabis use and Child Criminal Exploitation involvement, particularly those who are vulnerable to being drawn into the fringes of drug market supply and the associated risks. The services work as part of a multi-disciplinary team across the City and in 2023/24 worked with 25 young people as part of the offer.

New Leaf Rapid

where they have been found in possession of a banned substance, benefitted from additional funding during this year. During 2023/34 the service received 69 referrals. 40 were supported through for 1:1 and 29 were seen in workshops.

ACHIEVEMENTS AND PERFORMANCE

Demonstrating Effectiveness Individuals, Families & Communities

BDP uses an outcome monitoring tool the Treatment Outcome Profile (TOP) which is in use across all adult treatment services in England, to demonstrate the impact of alcohol and drug treatment services. Public Health England estimate a benefit cost ratio for drug treatment of 4:1, i.e. every £1 spent on drug treatment saves £4 on crime and health care costs; for alcohol the ratio is 3:1, a saving of £3 for every £1 spent.

14

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

indicators:

----- Start of picture text -----
Service Delivery: accessible, high quality and responsive. Q1 Q2 Q3 Q4
Number of assessments undertaken 88 87 77 100
% of service users waiting >3 weeks for a shared care 21.00 11.00 15.00 23.00
% of shared care clients with an in date medication prescribing 98.40 98.60 99.50 99.50
risk assessment
% of eligible service users who have had a Hepatitis C Test in this 66.00 66.00 69.50 71.70
treatment journey
% of eligible service users who have been supplied with Naloxone 44.60 43.80 51.60 60.00
in this treatment journey
% of clients who are retained in treatment for longer than 12 74.60 67.60 68.80 54.30
weeks
% of injecting drug users in Treatment who had reduced or ceased 87.30 85.00 84.00 82.50
injecting after first 6 months
----- End of picture text -----

In addition to the increase in the number of people benefitting from drug or alcohol treatment services, it is also feedback from individuals and our partners that really demonstrates the quality and impact of the services BDP delivers.

Adults told us:

BDP have saved my life, time and time again. I know I can come back whenever I need you and - An email to BDP

there is something for everyone. You have something on cognitive behavioural science, one thing on fellowships. Then organisation that is working. - Feedback left in advice centre feedback box

I only had one session with my new shared care worker and I felt so heard and so understoodshe listened and just got me so quickly- I know what I need to do next - Feedback given to Shared Care Manager

Children and Young People we support told us:

Feedback from other organisations and partners also illustrates the value and effectiveness of our services and our role in supporting other organisations to work effectively with people with drug and alcohol problems:

like you makes me feel even more excited about working in this field every day. Local partner agency worker after visiting Creative Communities

I did some interviews with people who use spice at BDP a few weeks ago, facilitated by Ed and was deeply impressed by the services and programs run by BDP - Postdoctoral Research Associate, Addiction and Mental Health Group (AIM)

15

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

You are a trusted source of information about drugsahead of the curve - Police Officer

Demonstrating Effectiveness: Reducing Drug-Related Deaths

Reducing Overdose

related deaths and we have supported and introduced numerous initiatives that aim to reduce the number of drug-related deaths in Bristol and beyond. We have continued to focus on providing targeted harm reduction and overdose prevention advice to a range of groups where risk is high to reduce the chances of overdose.

The last year has seen the introduction of Nitazenes into the illicit drug market. These synthetic opioids are very high-strength and have been the cause of increases in fatal and non-fatal overdoses in Bristol and further afield at various points during the year and are likely to remain an ever-present risk moving forward.

reduction charity The Loop in partnership with BCC and BDP.

The trailblazing evidence-based health service aims to reduce harm from dependent and high-risk drugtaking, increase understanding of local drug markets, and share information with stakeholders, including police and health services, to support harm reduction messages to wider drug using communities. It is funded by BCC hosted at 11 Brunswick Square by BDP.

Our focus to protect people who use opioids has remained to make Naloxone (administered via intramuscular injection) and Nyxoid (administered via a nasal spray) as widely available as possible. This year, we continued the training staff from Avon and Somerset Police to carry and use Nyxoid, with hundreds of individuals being trained. BDP staff ran weekly training courses in how to use Naloxone. This service is bookable online and taken up by professionals across housing, health care and other related services. We continued to offer Naloxone to all opioid users in direct access services and all shared care service users every three months as part of their routine appointments.

Reducing Transmission of Blood-Borne Viruses

We continued to work towards the micro-elimination of Hepatitis C (the WHO global hepatitis strategy to reduce new infections by 90%), working in partnership with Hep C U Later, the Hep C Trust, University Hospital Bristol Western and Gilead Research. This funded a full-time post for the second year running to assertively reach, test and support access to treatment for Hepatitis C. In the last 12 months, 80 people who had previously tested positive for Hep C are now free of Hepatitis C and we have continued to support access to treatment with creativity and flexibility, offering home visits and life-saving medication deliveries. We tested 857 people across our services and have continued to train all staff to be able to offer BBV testing.

Increasing Needle and Syringe supply

Encouraging injectors to take at least one clean needle per injection remains a key priority to prevent the spread of blood borne viruses and associated morbidity. Our home delivery service and keeping supplies accessible through the Pharmacy Needle Exchange scheme remained a focus .

Safeguarding

-referring vulnerable adults to social care, additional support from ROADS Social Worker has continued. The ROADS Safeguarding Lead has provided mandatory training for staff across the partnership.

16

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

BDP has introduced a new dedicated Safeguarding Lead role held by Sarah Price, one of our Team Leads. This has resulted in further strengthening of recording and monitoring processes. Safeguarding concerns on the caseload are reviewed on a fortnightly basis and safeguarding is recorded on the corporate Risk Register, which is reviewed by the trustees at their six-weekly meeting. The number of successful adult safeguarding referrals made by BDP has increased dramatically following the training. Referrals to

We have continued to be or experiencing, Child Criminal Exploitation and Child Sexual Exploitation. We have contributed to local Safer Options meetings. Our Youth Team continues to manage high levels of risk amongst Children Affected by Substances (CABS) and is vigilant to any changes in County Lines where young people from Bristol are exploited in the drugs supply chain elsewhere. Funding for our New Leaf and New Leaf Rapid projects was extended, allowing us to continue this important preventative work with young people whose entrenched cannabis use increases their vulnerability or whose drug use has risked school exclusion. Our Transformation Programme (formerly ADDER) funded roles have continued to support adults where Anti-Social Behaviour is often an indication of criminal exploitation of vulnerable adults.

Challenging Prejudices

This continues to underpin all that BDP does, both in our day-to-day work with one of the most marginalised groups in our society where health inequalities are stark, and in our relationships with other organisations. We take all opportunities to get involved in training current and future workforces to raise the needs of people with drug and alcohol problems and to highlight the impact of the prejudices they face, with examples for student pharmacists described earlier.

FINANCIAL REVIEW

The net financial result for the year shows a surplus of funds for the year of £69,010. This compares with a surplus of £42,629 in the previous year. This surplus has been achieved by increasing income by £430,563 against budget projections as a result of additional ROADS contract income linked to

The accumulated funds at the year-end totalled £4,096,129 (2022/23 £4,027,119). £4,562,239 is the total income for the year. Restricted funds are £339,630 (2022/23: £421,472) and unrestricted funds were £3,756,499 (2022/23: £3,605,647).

Principal Funding Sources

Income received in 2023/24 was £4,562,239 (2022/23: £4,238,551).

Of the full ye income, £998,164 (2022/23: £999,440) was paid to partners for sub-contracted service delivery including payments to community pharmacies for delivery of Needle and Syringe Programmes, and to other sub-contractors AWP and BrisDoc Health Care.

The Board of Trustees would like to express its thanks to all the organisations that have provided funding, in particular Bristol City Council, which remains the Charity largest funder.

Investment Policy

Our investment objectives are to achieve growth and income. We aim to generate sustainable returns that allow us to achieve our charitable objectives while protecting the capital value of our investments. We recognise that every investment carries risk, and we manage these risks to ensure that they are moderate, and we are willing to accept fluctuations in the value of our assets in pursuit of our investment objectives.

17

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

BDP will balance risk and return to achieve our investment objectives. We will seek to achieve our investment goals through a mix of investments with different risk profiles to achieve a diversified portfolio of investments that suit our needs. As stated above, we will balance the risk of lower returns versus the risk of damaging reputation, financial stability or alienating support.

We invest our financial resources in line with our objectives, risk appetite, and investment policy. An initial investment part way through the year with our Investment Manager, Cazenove, had yielded a return of 5.1% by the year end. However, our investment time horizon is long-term, and we aim to invest in funds for the long term. We recognise that investing is a long-term activity that requires a disciplined approach to generate sustainable returns.

We will ensure that our charity has sufficient liquidity to meet our financial commitments, including grants and other charitable activities. We will invest in liquid assets and maintain an appropriate level of cash reserves to ensure that we can access our money when we need it.

We will measure the performance of our investments based on the total return, Consumer Prices Index (CPI) plus 4%, and other appropriate benchmarks. We will review our performance regularly and adjust our investment strategy as necessary.

Reserves Policy

As part of the annual planning and budget-setting cycle, the Board of Trustees review and approve the level of readily available reserves appropriate to the scale, complexity, and risk profile of BDP. The Finance and General Purposes Committee keep this under review. The provision made for lease dilapidation commitments increased to £210,000.

service in the event of: late payment of funds; where contract payments are made in arrears; unexpected contingency; to enable BDP to compete in competitive procurement processes against Board of Trustees identified the need to retain unrestricted reserves necessary for 26 weeks operating costs, a budgeted figure of £2,778,412 for the financial year 2024/25. We can clearly demonstrate that we retain sufficient resources to deliver services with confidence and to manage any negative impact

The Board of Trustees has built up healthy reserves to allow for uncertainty and to support vital services not funded by our current ROADs contract. With the ongoing uncertainty of commissioning of the majority of our services in 2024/25, the board have agreed that we retain £1million in reserves, to cover this continued uncertainty, particularly where some programmes are not funded in full. From experience of commissioning in the city, there is a real possibility of an extended decision schedule, so we need this funding to continue vital services and to allow us time to find funds for unfunded streams for these programmes, from alternative sources. We aim to do this with a fundraising strategy we will agree in early 2024/25.

PRINCIPAL RISKS AND UNCERTAINTIES

The Board of Trustees considers and approves a risk map and management plan each year, which identifies the risks to which BDP may be exposed. The methodology used to assess risk evaluates these against five measures of likelihood of occurrence and five measures of impact. Mitigation measures are reviewed, and a post evaluation score agreed with retained risks categorized as red, amber or green. This risk register is reviewed regularly to ensure that: risk levels are appropriate; that new risks are identified; and that a management plan is in place to minimise and mitigate BDP s exposure to those risks.

18

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

BDP s new High Level Safeguarding Risk Register is reviewed fortnightly by SLT and at each 6-weekly Trustees Board meeting.

The Board of Trustees considers exceptional risks routinely at its meetings when it receives reports of emerging or unforeseen risks.

The main risks to the charity, which would constrain its ability to deliver services to people with alcohol and drug problems on the scale in which they are required, are:

Loss of funding

BDP mitigates this risk by providing high quality and effective services which are valued by commissioners, attractive to prospective commissioners, and credible and effective for people with alcohol or drug problems and people in those communities which are impacted by these.

We continue to take steps to diversify our funding base to increase resilience, while recognising that securing income on the scale required to deliver reliable services to vulnerable adults and children from sources other than the Public Sector is not realistic.

value contract, which was extended to 31 March 2025 this year, at the Year Five funding value. The TYS contract has been extended to align with the ROADS contract to 31 March 2025, after which the two services will be commissioned as one entity.

BDP has developed a strong partnership consisting of national and local partners that it feels offers it the best chance of a successful re-tender for Bristol substance use services, providing a degree of certainty over the next five years, with potential for further extensions of a further four years. A successful bid will see BDP maintain similar levels of net income, workforce and range of services although the partnership structure will necessitate changes to organisational and operational structures.

Workforce

We recognise that there is a cost of living issue which is affecting staff in our sector particularly in front line roles and are working to offer a strong employment package alongside a pay package linked to JNCC increases to ensure that we have high quality applications for roles and can recruit and retain staff. We have been largely very successful in recruitment activity over the course of the year with a significant number of additional roles filled quickly in order to support the rapid roll-out of additional services.

The Board of Trustees agreed a change to the annual leave policy requested by Unison, that now sees staff accrue additional leave on each working anniversary up to the maximum entitlement a change from the previous approach to accumulated increases at three and five years.

The last year saw the introduction of an Employee Assistance Programme (EAP) which is a confidential employee benefit designed to help you deal with personal and professional problems that could be affecting your home life or work life, health and general wellbeing.

This includes:

Life support: Access to counselling for emotional problems and a pathway to structured therapy sessions (employees only) at your convenience;

19

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

Disaster & Business Continuity

disaster situations. This has not been invoked within the last year.

Insurance cover is reviewed annually to ensure it is for money.

Reputational Damage

Policies, procedures, audit, complaints procedures, and open communication mitigate risk of commissioners, current and potential service users and other organisations losing confidence in the organisation. BDP is held in high regard by service users, commissioners and other organisations as evidenced throughout this report.

Recognising that significant changes within the organisation as seen within the last year have the potential to exacerbate reputational risk, this has been monitored and mitigated against via the corporate Risk Register which is reviewed at six-weekly board meetings, with Committees reviewing

PLANS FOR THE FUTURE

ensure that the charity can continue to flourish and develops services in line with emerging need.

With the process for Bristol ROADS recommissioning having commenced this year, the differing approach from BCC guarantees significant change in the year ahead. The revised approach has necessitated a partnership bid which will have significant structural and operational change for BDP.

diversification of income considering other commissioned opportunities alongside grant funding and charitable opportunities.

Workforce

As above, Bristol ROADS recommissioning will be the defining event of the next year. A successful bid will see BDP retain services roughly equivalent to its current proportion of the treatment system, income and workforce albeit that there will be a change to working more closely in partnership with other charities, both local and national.

bidder. We will know the outcome of this process early in the new financial year and will be able to enact any contingency actions in the event of this worst-case scenario.

bespoke pay structure. This sets out five pay scales with lower and upper limits, each linked to different roles within the organisation, including Service Managers and the CEO. The charity periodically reviews

20

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

its pay structure to ensure that remuneration for roles is broadly in line with that offered by other organisations delivering similar activities, most recently completed in January 2023.

Inflation has stabilised however the cost of living crisis continues for most. It will clearly have greatest our skilled and passionate workforce, ensuring that their knowledge of related issues - benefits, housing, and money and debt management -

BDP has seen greater success over the last year in successful recruitment with an additional eighteen roles filled quickly to enable a rapid roll-out of additional services.

Children and Young People

For the first time, Targeted Youth Services (TYS) will be commissioned by BCC within the same contract as the adult services from 1 April 2025. Given that these services will be tendered as a sole contract, -orcontracts.

As above, BDP has developed a strong partnership consisting of national and local partners that it feels offers it the best chance of a successful re-tender for Bristol substance use services, providing a degree of certainty over the next five years, with potential for further extensions of a further four years. A successful bid will see BDP maintain similar levels of net income, workforce and range of services although the partnership structure will necessitate changes to organisational and operational structures.

BDP continues to provide additional services to children and young people, such as its M32 group. These additional activities are currently funded from reserves with a key target for fundraised income to cover these costs.

Treatment and Support

Many of our ambitions for 2024/25 remain unchanged. We continue to work with one of the most support networks shrink with ageing; where their health deteriorates; and where stigma is alive and well.

We continue to campaign for drug and alcohol misuse to be seen as a health issue and one that requires a non-judgmental and trauma informed approach. At the heart of change for many people using opiates are Adverse Childhood Experiences for which opiates in particular provide a learned coping mechanism, embedded over many years. Improving our ability to support people who have experienced trauma, supporting them to develop alternative less harmful coping mechanisms will continue to underpin our activities.

BDP has adapted and supplemented its services in order to align to these local strategic objectives and to be recognised as local system leaders.

Other priorities include:

Reducing drug related deaths and improving health and wellbeing

21

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

We will continue to work with health professionals to accurately and swiftly diagnose health conditions and the need for drug and alcohol support to reduce drug related deaths. We continue to work with services launched due to the Transformation Programme.

Work with the health sector will include working to support undiagnosed or untreated health conditions, particularly respiratory illnesses frequently seen in our population. Opiates in particular suppress pain or symptoms associated with many health conditions and BDP has a key role to play in improving

and supporting pathways into primary and secondary care. Our enhanced nursing time, sub-contracted from BrisDoc Healthcare, will continue to significantly improve access to physical health care, including

Our funding secured from BrisD with a specific focus on our homeless population.

We will continue to work across and alongside all GP practices in the city to build trust and share the care of alcohol and drug users and increasing access to services. We have identified some areas of work where the system makes this access difficult and intend to run some pilot work with a few practices offering evening and weekend appointments and one to one rather than group services where we feel that will increase engagement .

Increasing contact with people using non-opiate drugs and alcohol in the night-time economy

Our digital information and harm reduction offer has significant reach and profile. We will continue to enhance it and therefore support people to reduce risk and harm linked with using non-opiates and alcohol. This will include continuing our partnership with the University of Bristol and Bristol Students Union to support harm reduction-driven policy. We also look forward to continuing to host and support The Loop to deliver their licensed Drug Safety Checking service here in Bristol.

Improving access to Hepatitis C treatments

BDP will continue to use the World Health Organisation (WHO) commitment to eliminating Hepatitis C to underpin our harm reduction work as we commit to increasing further, coverage of our Needle and Syringe Programme through a wider range of routes, including home delivery; increasing the number people who inject drugs engaged with Opioid Substitution Treatment; and increasing the number of people who start and successfully complete Hepatitis C treatment.

Reducing Stigma

Stigma remains the highest barrier to accessing treatment and recovery for many of our service users. For people from some black, African and minority ethnic (BAME) communities that stigma can seem insurmountable. We will continue to work alongside communities through our Diverse Communities Link Worker role, developing our Community Champion role to offer a bridge between people who need Service Level Agreement (SLA) with SARI to provide advice and training to BDP. We have contracted with them to run sessions with our Board and staff team as well as gaining their support in our recruitment process to help us increase diversity in the staff and Board.

Drug Control and Drug Market Changes

We will keep our radar finely attuned to shifts in drug markets and outbreaks of heroin usage in the UK, which has historically been aligned with periods of increased austerity, and disrupted education following the pandemic.

22

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

As mentioned throughout this report, the introduction of Nitazines into the illicit drug supply creates significant additional risk of drug-related deaths. BDP will remain alert to these risks and collaborate with partners across Bristol and beyond in order to both minimise and raise-awareness of the risks.

Research

We remain committed to developing and using the evidence of what works and research partnerships offer us a great opportunity to grow that evidence.

Preparation for Commissioning

2024, with the consultation process and the early-formation of a partnership approach in order to develop a successful bid for this already started.

We have conducted formal due diligence and selected a clinical partner that best complements our own expertise along with bringing together a range of local providers who we feel will support us in constructing the best system solution for Bristol. The tender opened at the end of the financial year with the bid having been submitted in May 2024.

In Conclusion

We will continue to remain vigilant to drug-market, policy, strategy and legislative changes that will impact people with alcohol and drug problems, their families and their communities. We will challenge policy changes which will increase harm and stigma. We will ensure that our workforce is flexible, advocate to reduce the harmful impact of a bleak financial outlook and the health inequalities which our service users experience.

We will continue to seek to secure funding for our activities which are additional to those formally commissioned, but which add real value to people and communities. As always these include our Youth Groups, Over 50s group, and our Creative Communities which offers of drama, choir, orchestra and

Our biggest challenge and priority for the forthcoming year remains to seek and create new ways of both those who fall in and out of treatment and those w to reaching more of that population in 2024/25 and recognise that this requires listening closely to what people want and then delivering with care, passion and creativity.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

Bristol Drugs Project is a charitable company limited by guarantee, incorporated on 3 April 1985 and registered as a charity on 14 May 1985.

The company was established under a Memorandum of Association that founded the objects and powers of the charitable company, and is governed under its Articles of Association. The Directors completed their review of the Memorandum and Articles of Association to ensure that, as well as being compliant with the Charities Act 2011 and Companies Act 2006, they are relevant to current patterns of drug and alcohol use, and contemporary policy. The changes agreed with the Charities Commission in March 2022 were adopted by the board at their Annual General Meeting (AGM) on 3[rd] October 2022. In the event of the company being wound up, members are required to contribute an amount not exceeding £1 each.

Board of Trustees (Directors)

23

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

The Directors of the company are also charity trustees for the purpose of charity law and under the company s Memorandum and Articles of Association are known as members of the Board of Trustees.

The Board of Trustees can have a minimum of 4 and a maximum of 15 members. The Board are very active, meeting approximately every 6 weeks, and are responsible for the strategic direction and policy of the charity, and for ensuring that its finances, systems and procedures are fit for purpose as set out in its Governance Framework. In addition, to adherence to the Nolan Principl the seven principles of public life Board members bring a wide range of business and professional skills to their role. The involvement of former service users as trustees is particularly important, ensuring the needs of beneficiaries of the charity are at the core of BDP policy and strategy.

At the year-end, the Board of Trustees had 13 members from a variety of backgrounds relevant to the charity and its management.

The Board of Trustees delegates operational management of the charity to a CEO, who in turn delegates responsibility for specific areas of service delivery, performance, and staff and volunteer management to senior managers.

Recruitment and Appointment and Changes to Board of Trustees

The charity operates a competency-based recruitment process, recruiting new Board members as required. Prospective Board members are interviewed by the Chair and CEO and invited to observe a Board meeting(s). The Board of Trustees then decides whether to invite a new member to join them and to stand for election at the next AGM.

The Memorandum and Articles require a third of the membership of the Board to retire annually, although they may stand for re-election at the next AGM.

Each trustee may normally serve for three terms of office, although any trustee may be asked to continue beyond this where the Board wishes to retain an individua s specific skills for an additional term for the benefit of the charity. BDP seeks to achieve a balance between longer-serving trustees who use their collective memory to provide continuit nd newly recruited trustees who strengthen skills and bring fresh perspective to the Charity.

Board of Trustees Induction and Training

All applicants for the Board of Trustees receive a Recruitment Pack which gives a role description, detailed information about the Charity s history, services, and staff, as well as their obligations as Board members. All are given the Charity Commissio s guide The Essential Trustee together with a copy of s Memorandum and Articles of Association and the latest financial statements. New members are encouraged to shadow services, and to participate in the charity s annual service planning and review day and in-house training; this enables them to gain an in-depth understanding of the charity s main activities to inform their decision-making.

Alternate Board meetings are preceded by an additional hour-long session, which focuses on a particular aspect of service delivery or relevant changes at national or local policy level. This enables trustees to review regularly key issues affecting the future direction of the charity and to ensure that due weight is given to key changes in government policy, structures or changes in patterns of alcohol or drug use.

Committees

A working party of trustees have conducted a review of organisational governance and initiated a new Committee structure, which was implemented at the end of the year. This has resulted in the creation of an additional Committee (People) and a restructure of responsibilities:

Trustees and meets normally every six weeks to review financial performance, recommend any actions

24

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

necessary to control financial risk, ensure service delivery within budget and agree significant capital expenditure.

The People Committee, has delegated authority from the Board of Trustees and meets quarterly to review all aspects of performance linked to people, HR, Safeguarding and EDI. The sub-group takes responsibility for the development of and adherence to all people policies.

Quality and Performance Committee has delegated authority from the Board and meets quarterly to ensure adequate and appropriate governance structures, processes and controls are in place throughout BDP to promote safe, high quality care, appropriate reporting to funders, achieve continuous improvement of care and to ensure the effective and efficient use of resources through evidence-based practice and research.

Senior Leadership Team (SLT)

This comprises Anna Smith, Chief Executive Officer, Lydia Plant, Director of Operations, Ben Judd, Director of Business Development and Katheryn Talboys, Service Manager. Karen Black, Interim Management Support has supported the SLT throughout the year.

at weekly meetings. The SLT is considered to be the key management personnel of the charity. Regular Senior Management Team meetings, which include Team Leaders, ensure effective communication and planning and serves to support managerial capacity and competency of Team Leaders.

Related Parties

Board of Trustees and SLT declare potential conflicts of interest to BDP annually, or when their circumstances change. Conflicts of interest relevant to the business of meetings are asked for by the Chair and declared as a standard agenda item at all trustee meetings.

Fundraising Policy

BDP did not employ professional fundraisers or commercial participators during this or previous periods and therefore the provisions of the Charity (Protection and Social Investment) Act 2016 do not apply to the C

The trustees (who are also directors of the charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the trustees are required to:

25

Bristol Drugs Project Limited

Report of the Trustees

For the year ended 31 March 2024

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The trustees are members of the charity, but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

Auditors

Godfrey Wilson Limited were re-appointed as auditors to the charitable company during the year and have expressed their willingness to continue in that capacity.

This report, including the Report, was approved by the Board of Trustees on 7 October 2024 and signed on its behalf by:

John Long, Chair, QPM, BA Hons, MA 11 Brunswick Square Bristol BS2 8PE

26

Independent auditors' report

To the members of

Bristol Drugs Project Limited

Opinion

We have audited the financial statements of Bristol Drugs Project Limited (the 'charity') for the year ended 31 March 2024 which comprise the statement of financial activities, balance sheet, statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Ethical Standard, and the provisions available for small entities, in the circumstances set out in note 5 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

27

Independent auditors' report

To the members of

Bristol Drugs Project Limited

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the report included within the report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the responsibilities statement set out in the report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

28

Bristol Drugs Project Limited

Independent auditors' report

To the members of

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The procedures we carried out and the extent to which they are capable of detecting irregularities, including fraud, are detailed below:

(1) We obtained an understanding of the legal and regulatory framework that the charity operates in, and assessed the risk of non-compliance with applicable laws and regulations. Throughout the audit, we remained alert to possible indications of non-compliance.

(3) We inspected the minutes of trustee meetings.

(4) We enquired about any non-routine communication with regulators and reviewed any reports made to them.

(5) We reviewed the financial statement disclosures and assessed their compliance with applicable laws and regulations.

(6) We performed analytical procedures to identify any unusual or unexpected transactions or balances that may indicate a risk of material fraud or error.

(7) We assessed the risk of fraud through management override of controls and carried out procedures to address this risk. Our procedures included:

Testing the appropriateness of journal entries;

Testing transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. Irregularities that arise due to fraud can be even harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

29

Independent auditors' report

To the members of

Bristol Drugs Project Limited

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting website at: www.frc.org.uk/auditorsresponsibilities. This description

Use of our report

This report is made solely to the members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the members those matters we are required to state to them in an report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the members as a body, for our audit work, for this report, or for the opinions we have formed.

Date: 7 October 2024

Alison Godfrey FCA (Senior Statutory Auditor)

For and on behalf of:

GODFREY WILSON LIMITED

Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

30

Bristol Drugs Project Limited

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2024

Note
Income from:
Donations and legacies
Charitable activities
4
Other trading activities
Investments
Total income
Expenditure on:
Raising funds
Total expenditure
7
Net gains on investments
Net income / (expenditure)
Transfers between funds
Net movement in funds
5
Reconciliation of funds:
Total funds brought forward
Total funds carried forward
Charitable activities: provision of
services		 Unrestricted
£
39,121
1,123,890
14,104
95,366
1,272,481
(4,003)
(1,228,608)
(1,232,611)
79,513
119,383
31,469
150,852
3,605,647
3,756,499		 Restricted
£
-
3,289,758
-
-
3,289,758
-
(3,340,131)
(3,340,131)
-
(50,373)
(31,469)
(81,842)
421,472
339,630		 2024
Total
£
39,121
4,413,648
14,104
95,366
4,562,239
(4,003)
(4,568,739)
(4,572,742)
79,513
69,010
-
69,010
4,027,119
4,096,129		 2023
Total
£
22,584
4,170,725
3,665
41,577
4,238,551
-
(4,195,922)
(4,195,922)
-
42,629
-
42,629
3,984,490
4,027,119

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 16 to the accounts.

31

Bristol Drugs Project Limited

Balance sheet

At 31 March 2024

Note
Fixed assets
Tangible assets
8
Investments
9
Current assets
Debtors
10
Current asset investments
Cash at bank and in hand
Liabilities
Creditors: amounts falling due within 1 year
11
Net current assets
Total assets less current liabilities
Provisions for liabilities
12
Net assets
14
Funds
16
Restricted funds
Unrestricted funds:
Designated funds
General funds
Total charity funds		 £
605,785
700,603
1,987,550
3,293,938
(1,224,013)		 2024
£
93,063
2,143,141
2,236,204
2,069,925
4,306,129
(210,000)
4,096,129
339,630
54,668
3,701,831
4,096,129		 2023
£
51,967
16,000
67,967
645,108
2,657,658
1,713,874
5,016,640
(891,488)
4,125,152
4,193,119
(166,000)
4,027,119
421,472
6,579
3,599,068
4,027,119

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 7 October 2024 and signed on their behalf by

J Long - Director and Chair M Lea - Treasurer

32

Bristol Drugs Project Limited

Statement of cash flows

For the year ended 31 March 2024

Cash flows from operating activities:
Net movement in funds:
Adjustments for:
Dividends, interest and rents from investments
Profit on the sale of fixed assets
Gains on investments
Depreciation
(Increase) / decrease in debtors
Increase in creditors
Increase in provisions
Net cash provided by / (used in) operating activities
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of investments
Purchase of tangible fixed assets
Profit on the sale of fixed assets
Net cash used in investing activities
Decrease in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Analysed as:
Cash at bank and in hand
Current asset investments
Cash held in investment portfolio		 2024
£
69,010
(95,366)
(9,834)
(79,513)
17,188
39,323
332,525
44,000
317,333
95,366
(1,479,500)
(58,284)
9,834
(1,432,584)
(1,115,251)
4,371,532
3,256,281
1,987,550
700,603
568,128
3,256,281		 2023
£
42,629
(41,577)
-
-
12,154
(564,126)
223,330
-
(327,590)
41,577
-
(47,586)
-
(6,009)
(333,599)
4,705,131
4,371,532
1,713,874
2,657,658
-
4,371,532

Analysis of changes in net debt

The charity has not provided an analysis of changes in net debt as it does not have any long term financing arrangements.

33

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

1. Company status The company is a registered charity and a company limited by guarantee without share capital, incorporated in England and Wales. The guarantors are the council members to the extent of £1 each.

The address of the registered office is 11 Brunswick Square, Bristol, BS2 8PE.

2. Accounting policies

a) Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. There are no material departures from the SORP and FRS 102.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value, unless otherwise stated in the relevant accounting policy note. The accounts are presented in sterling which is also the functional currency of the charity.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate. The charity holds unrestricted, general reserves of £3,701,831 and a cash balance of £1,987,550. There are no material uncertainties about the charity's ability to continue as a going concern.

c) Income

Incoming resources represent the amount derived from contracts, grants and donations receivable during the year. All income is credited to revenue when the charity is entitled to the income, any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Many of the charity's funding streams, whilst having certain conditions attached which must be met to fulfil the charity's obligations, are actually contracts for service. Thus by providing the service for the year, the obligation attached to the contract is released with any residual deficit or benefit on the contract value being at the risk of or for the benefit of the charity. Income received in advance of provision of services under contracts is deferred until criteria for income recognition are met.

34

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

2. Accounting policies (continued)

c) Income (continued)

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Expenditure and irrecoverable VAT

Expenditure is included in the financial statements on an accruals basis. Expenditure is charged directly to the provision of services wherever possible.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

e) Allocation of support and governance costs

f) Funds

Unrestricted general funds are available for use at the discretion of the board of trustees in furtherance of the general objectives of the charity.

Restricted funds are funds which have been given for a specific purpose by the donor or statutory body or by the purpose of the appeal in which the funds are raised. Expenditure which meets these criteria is charged to the fund, together with fair allocation of management and support costs on an employee basis.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

35

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

2. Accounting policies (continued)

g) Tangible fixed assets

Depreciation of fixed assets is calculated to write off their cost less any residual value over their estimated useful lives as follows:

Motor vehicles, fixtures, fittings and office equipment are depreciated on a straight line basis over 5 years.

Assets are capitalised where the cost exceeds £5,000. A full depreciation is charged in the year of acquisition.

h) Investments

Listed investments traded on a recognised stock exchange are stated at fair value at the reporting date, which is deemed to be their market value. Any gain or loss, whether realised or unrealised, is taken to the Statement of Financial Activities.

Investments in associated companies are held at cost, less provision for any impairment.

i) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

j) Current asset investments

Current asset investments consist of cash held on deposit in interest bearing accounts. Such investments are measured at their fair value.

k) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

l) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

m) Operating leases

Rentals paid under operating leases are charged to the statement of financial activities as they fall due.

n) Pensions

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £47,303 (2023: £41,490). Contributions totalling £10,662 (2023: £8,548) were payable to the fund at the balance sheet date and are included in creditors.

36

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

2. Accounting policies (continued)

o) Provisions

A provision is recognised in the balance sheet when the charity has a present legal or constructive obligation as a result of a past event, that can be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

p) Financial instruments

The charity only has financial assets and financial liabilities that qualify as basic financial instruments, being trade and other debtors and creditors. Basic financial instruments are initially recognised at transaction value, and are subsequently recognised at their settlement value. Any losses arising from impairment are recognised in the statement of financial activities. No impairment losses were recognised in the current or prior year.

q) Critical accounting judgements and key sources of estimation uncertainty

In the application of the accounting policies, which are described above, the board of trustees is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgements and estimates that the trustees have made in the process of applying the accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Provisions for lease dilapidations are recognised when a reliable estimate of the outflow of future economic benefit which will be required to settle any future obligation can be made. Further detail is provided in note 12.

Key management personnel are considered to be the board of trustees and the senior management team. As trustees, the board of trustees is not remunerated. The remuneration of key management personnel is disclosed in note 6.

Delays in obtaining final grant and contract agreements mean there is a degree of judgment involved in determining when entitlement to accrued income is met.

37

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

3. Prior period comparatives: statement of financial activities

Income from:
Donations and legacies
Charitable activities
Other trading activities
Investments
Total income
Expenditure on:
Charitable activities
Total expenditure
Net income / (expenditure) and net
movement in funds		 Unrestricted
funds
£
22,392
228,181
1,325
41,577
293,475
(395,520)
(395,520)
(102,045)		 £
192
3,942,544
2,340
-
3,945,076
(3,800,402)
(3,800,402)
144,674
Restricted
funds		 2023 Total
£
22,584
4,170,725
3,665
41,577
4,238,551
(4,195,922)
(4,195,922)
42,629

38

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

4. Income from charitable activities

Income from charitable activities
BrisDoc
Bristol City Council (ADDER & OHID)
Bristol City Council (ROADS)
Bristol City Council (SSMTR)
Creative Youth Network
Hepatitis C
Next Link
NHS BNSSG CCG (Vanguard)
Rough Sleeping Drug Alcohol Treatment Grant
(Shared Care & Outreach)
Second Step
University Bristol & Weston NHS
Other charitable income less than £9,999
Total income from charitable activities
Prior period comparative
Bristol City Council (ADDER)
Bristol City Council (ROADS)
Creative Youth Network
CHK Foundation
Avon and Wiltshire Partnership (Hepatitis C)
NHS BNSSG CCG (Vanguard)
Rough Sleeping Drug Alcohol Treatment Grant
(Street Intervention)
Rough Sleeping Drug Alcohol Treatment Grant
(Substance Misuse Liaison Connect)
University Bristol & Weston NHS
Other charitable income less than £9,999
Total income from charitable activities		 £
30,000
518,190
-
236,759
23,797
38,003
35,502
43,131
135,688
30,974
-
31,846
1,123,890
£
-
-
142,676
11,142
22,673
22,087
-
-
-
29,603
228,181
Unrestricted
funds
Unrestricted
funds		 Restricted
funds
£
-
-
3,279,893
-
-
-
-
-
-
-
8,665
1,200
3,289,758
Restricted
funds
£
515,153
3,279,711
-
-
-
-
37,750
92,825
17,105
-
3,942,544		 2024 Total
£
30,000
518,190
3,279,893
236,759
23,797
38,003
35,502
43,131
135,688
30,974
8,665
33,046
4,413,648
2023 Total
£
515,153
3,279,711
142,676
11,142
22,673
22,087
37,750
92,825
17,105
29,603
4,170,725

Government grants

The charity receives government grants, defined as funding from The National Lottery Community Fund to fund charitable activities. The total value of such grants in the period ending 31 March 2024 was £Nil (2023: £7,523). There are no unfulfilled conditions or contingencies attaching to these grants in the current or prior year.

39

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

5. Net movement in funds

Net movement in funds are stated after charging:

Depreciation of tangible fixed assets
Auditors' remuneration (ex VAT)
Trustees' remuneration
Trustees' reimbursed expenses
Trustees' indemnity insurance
Operating lease payments:
Rent
Equipment		 2024
£
17,188
8,450
Nil
Nil
736
122,146
4,236		 2023
£
12,154
7,500
Nil
75
736
91,664
4,012

In the prior year trustee reimbursed expenses relate to travel and subsistence costs for 2 trustees.

In common with other charities of our size and nature we use our auditors to assist with the preparation of the financial statements. Our auditors have also provided consultancy services to the charity during the year.

6. Salaries

Staff costs were as follows:

Gross salaries
Employers national insurance
Pensions		 2024
2023
£
£
2,462,669
2,175,111
211,149
194,020
47,303
41,490
2,721,121
2,410,621

Two employees (2023: one) earned a salary in the range of £60,000 - £70,000 per annum.

Included in gross salaries are redundancy and termination costs totalling £6,000, comprising wholly of ex-gratia payments. Redundancy and termination costs have been funded from unrestricted general funds (note 16).

Average number of employees (full time equivalent)
Average number of employees (headcount)		 2024
No.
78
93		 2023
No.
73
86

The total remuneration of key management personnel (as defined in note 2 (q) above) amounted to £250,396 (2023: £266,558).

40

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

7. Expenditure on charitable activities

Staff costs
External supervision
Legal and professional
Recruitment
Salaries, employer's NI and
pensions (note 6)
Temporary staff
Training and development
Travel and subsistence
Direct service costs
Breaking Free/SARI
Client service access and
translation
Client workshop
Contingency management and
client research
Health care intervention
Youth groups
Needle and syringe programme
Volunteer expenses
Partner payments
Payments to joint providers
Premises costs
Premises costs		 Raising
funds
£
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-		 Charitable
activities
£
9,813
-
22,230
2,663,023
30,450
23,074
26,527
2,775,117
22,495
11,768
25,356
4,177
28,925
5,255
211,910
4,986
314,872
998,164
998,164
161,252
161,252		 Support and
governance
costs
2024 Total
£
£
-
9,813
3,438
3,438
-
22,230
58,098
2,721,121
-
30,450
-
23,074
156
26,683
61,692
2,836,809
-
22,495
-
11,768
-
25,356
-
4,177
-
28,925
-
5,255
-
211,910
-
4,986
-
314,872
-
998,164
-
998,164
-
161,252
-
161,252

41

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

7. Expenditure on charitable activities (continued)

Other costs
Audit fees
Bank charges
Depreciation
Equipment hire
Health, safety and welfare
Insurance
IT costs and support
Marketing and events
Non capital equipment
Printing, postage and stationery
Professional fees and consultancy
Provisions for liabilities
Subscriptions
Telephone charges
Sub-total
Allocation of support and
governance costs
Total expenditure		 Raising
funds
£
-
-
-
-
-
-
-
-
-
-
4,003
-
-
-
4,003
4,003
-
4,003		 Charitable
activities
£
-
870
17,188
4,236
12,578
19,334
40,815
7,772
27,730
11,465
43,286
44,000
785
16,707
246,766
4,496,171
72,568
4,568,739		 Support and
governance
costs
£
10,140
-
-
-
-
736
-
-
-
-
-
-
-
-
10,876
72,568
(72,568)
-		 2024 Total
£
10,140
870
17,188
4,236
12,578
20,070
40,815
7,772
27,730
11,465
47,289
44,000
785
16,707
261,645
4,572,742
-
4,572,742

Total governance costs were £12,624 (2023: £11,417).

42

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

7. Expenditure on charitable activities (continued) Prior year comparative

Staff costs
External supervision
Legal and professional
Recruitment
Salaries, employer's NI and pensions (note 6)
Staff benefits and childcare vouchers
Temporary staff
Training and development
Travel and subsistence
Direct service costs
Breaking Free/SARI
Client service access and translation
Client workshop
Contingency management and client research
Health care intervention
Youth groups
Needle and syringe programme
Volunteer expenses
Partner payments
Payments to joint providers
Premises costs
Premises costs		 Charitable
activities
£
9,367
-
15,152
2,334,329
24
33,713
32,077
28,437
2,453,099
17,810
11,568
11,242
1,867
32,766
5,560
224,320
5,369
310,502
999,440
999,440
155,319
155,319		 Support and
governance
costs
2023 Total
£
£
-
9,367
1,681
1,681
-
15,152
76,292
2,410,621
-
24
-
33,713
-
32,077
-
28,437
77,973
2,531,072
-
17,810
-
11,568
-
11,242
-
1,867
-
32,766
-
5,559
-
224,320
-
5,369
-
310,502
-
999,440
-
999,440
-
155,319
-
155,319

43

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

7. Expenditure on charitable activities (continued) Prior year comparative (continued)

Other costs
Audit fees
Bank charges
Depreciation
Equipment hire
Health, safety and welfare
Insurance
IT costs and support
Marketing and events
Non capital equipment
Other
Printing, postage and stationery
Professional fees and consultancy
Subscriptions
Telephone charges
Sub-total
Allocation of support and governance costs
Total expenditure		 Charitable
activities
£
-
763
12,154
4,012
14,535
17,922
23,497
10,329
7,011
8,543
15,806
58,147
2,988
14,146
189,853
4,108,213
87,709
4,195,922		 Support and
governance
costs
£
9,000
-
-
-
-
736
-
-
-
-
-
-
-
-
9,736
87,709
(87,709)
-		 2023 Total
£
9,000
763
12,154
4,012
14,535
18,658
23,497
10,329
7,011
8,543
15,806
58,147
2,988
14,146
199,589
4,195,922
-
4,195,922

44

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

8. Tangible fixed assets

Motor
vehicles
£
Cost
At 1 April 2023
63,832
Additions for the year
19,353
Disposals
(9,834)
At 31 March 2024
73,351
Depreciation
At 1 April 2023
63,832
Charge for the year
1,703
On disposals
(9,834)
At 31 March 2024
55,701
Net book value
At 31 March 2024
17,650
At 31 March 2023
-
9.
Investments
£
£
Market value at 1 April 2023
-
16,000
Additions
1,479,500
-
Gains / (losses)
79,513
-
568,128
-
2,127,141
16,000
Investments at market value comprise:
Listed investments
Cash held by investment manager pending reinvestment
Investments in Associate
Investments in
Associates
Listed
investments
Total investments at 31 March
2024
Movement in cash held by
investment manager		 £
311,730
38,931
-
350,661
259,763
15,485
-
275,248
75,413
51,967
2024
£
16,000
1,479,500
79,513
568,128
2,143,141
2024
£
1,559,013
568,128
16,000
2,143,141
Fixtures,
fittings and
computer
equipment		 Total
£
375,562
58,284
(9,834)
424,012
323,595
17,188
(9,834)
330,949
93,063
51,967
2023
£
16,000
-
-
-
16,000
2023
£
-
-
16,000
16,000

45

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

9. Investments (continued)

Details of investments in associates undertakings

Details of the investments in which the group holds 20% or more of the nominal value of any class of share capital are as follows:

Country of Proportion of voting rights
Undertaking incorporation Holding and shares held
2024 2023
Social Impact Bristol England and Wales Ordinary 33% 33%
Limited Shares

The principal activity of Social Impact Bristol Limited is to work with some of Bristol's most entrenched rough sleepers. The address of its registered office is 5th Floor, 3 Thomas More Square, London, E1W 1YW.

Social Impact Bristol contract with Bristol City Council ended on 31 March 2021 and the company ceased trading on that date. The Directors have commenced proceedings to wind up the company and a voluntary liquidator was appointed on 18 May 2023. Upon wind up, any remaining funds will be distributed to investors.

10. Debtors

Amounts falling due within 1 year
Trade debtors
Prepayments
Other debtors
Amounts falling due after more than 1 year
Rent and deposits		 2024
£
569,503
33,861
283
603,647
2,138
605,785		 2023
£
494,961
24,045
123,964
642,970
2,138
645,108

46

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

11. Creditors

Amounts falling due within 1 year
Trade creditors
Accruals
Other taxation and social security
Deferred income (see below)
Other creditors
The movement in deferred income was as follows:
Balance at beginning of year
Released during the year
Deferred during the year
Balance at end of year		 2024
£
255,789
87,418
57,974
817,761
5,071
1,224,013
2024
£
421,173
(348,496)
745,084
817,761		 2023
£
231,714
100,458
44,787
421,173
93,356
891,488
2023
£
196,586
(60,453)
285,040
421,173

Deferred income relates to income received in advance of delivery of services.

12. Provision for liabilities

Provision for lease dilapidation 2024
£
210,000		 2023
£
166,000

Included within the leases for the charity's rented premises are dilapidation clauses. The trustees consider they are able to quantify the expected cost of the lease dilapidations, and have consequently included a provision of £210,000 (2023: £166,000) in the accounts.

47

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

13. Guarantees and other financial commitments

The charity had operating leases at the year end with total future minimum lease payments as follows:

Guarantees and other financial commitments
The charity had operating leases at the year end with total future
follows:		 minimum lease payments as
Amount falling due:
Within 1 year
Within 1 - 5 years		 2024
£
69,301
63,441
132,742		 2023
£
68,024
63,441
131,465

14. Analysis of net assets between funds

Analysis of net assets between funds
General
funds
2024
£
Tangible fixed assets
93,063
Investments
2,143,141
Current assets
1,914,393
Current liabilities
(238,766)
Provisions
(210,000)
Total net assets at 31 March 2024
3,701,831
Prior year comparative
General
funds
2023
£
Tangible fixed assets
51,967
Investments
16,000
Current assets
3,985,281
Current liabilities
(288,180)
Provisions
(166,000)
Total net assets at 31 March 2023
3,599,068		 Designated
funds
2024
£
-
-
591,779
(537,111)
-
54,668
2023
£
-
-
199,707
(193,128)
-
6,579
Designated
funds		 Restricted
funds
2024
£
-
-
787,766
(448,136)
-
339,630
2023
£
-
-
831,652
(410,180)
-
421,472
Restricted
funds		 Total funds
2024
£
93,063
2,143,141
3,293,938
(1,224,013)
(210,000)
4,096,129
Total funds
2023
£
51,967
16,000
5,016,640
(891,488)
(166,000)
4,027,119

15. Financial instruments at fair value

Financial assets measured at fair value 2024
£
1,559,013		 2023
£
-

Financial assets measured at fair value comprise listed investments.

48

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds

Restricted funds
ADDER
ROADS APPS/SMART
ROADS Complex Needs
Veterans
Total restricted funds
Unrestricted funds
Designated funds:
50+ Get Back Out There
ADDER
Creative Communities
Dentaid Service
Hepatitis C Engagement Worker
Missing Link
National Lottery - New Roots
New Leaf Rapid
Safe Inhalation Pipe Prevention
Second Step Link Service
Special Allocation Service
Sub total designated funds
ROADS Early Engagement & Intervention
ROADS Substance Misuse Liaison
Street Intervention Service		 At 1 April
2023
£
31,469
-
-
166,077
197,960
25,966
421,472
653
-
-
-
1,107
-
4,578
(5,720)
5,961
-
-
-
6,579		 Income
£
-
257,611
666,908
990,765
1,374,474
-
3,289,758
-
463,141
61,049
30,000
38,003
35,502
-
43,130
4,084
30,975
7,983
32,746
746,613		 £
-
(257,611)
(666,908)
(1,012,831)
(1,402,781)
-
(3,340,131)
(653)
(426,096)
(47,349)
(3,314)
(36,415)
(29,370)
(7,168)
(37,410)
(9,633)
(30,975)
(7,983)
(32,746)
(669,112)
Expenditure		 £
(31,469)
-
-
-
-
-
(31,469)
-
(37,045)
-
-
-
-
2,590
-
-
-
-
-
(34,455)
Transfers
between funds		 Gains /
(losses)
£
£
-
-
-
-
-
-
-
144,011
-
169,653
-
25,966
-
339,630
-
-
-
-
-
13,700
-
26,686
-
2,695
-
6,132
-
-
-
-
-
412
-
-
-
-
-
-
-
49,625
At 31 March
2024

49

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued)

Movement in funds (continued)
Unrestricted funds (continued)
Designated funds (continued):
Sub total brought forward
Targeted Youth Service
Transformation Service
Young Peoples Service
Youth Alcohol Drug Diversion
Designated funds less than £9,999
Total designated funds
General funds
Total unrestricted funds
Total funds
Connect Substance Misuse Liaison		 At 1 April
2023
£
6,579
-
-
-
-
-
-
6,579
3,599,068
3,605,647
4,027,119		 Income
£
746,613
102,942
23,797
96,932
142,144
3,264
7,228
1,122,920
149,561
1,272,481
4,562,239		 £
(669,112)
(102,942)
(29,574)
(96,932)
(155,843)
(3,264)
(2,185)
(1,059,852)
(172,759)
(1,232,611)
(4,572,742)
Expenditure		 £
(34,455)
-
5,777
-
13,699
-
-
(14,979)
46,448
31,469
-
Transfers
between funds		 Gains /
(losses)
£
-
-
-
-
-
-
-
-
79,513
79,513
79,513		 £
49,625
At 31 March
2024
-
-
-
-
-
5,043
54,668
3,701,831
3,756,499
4,096,129

Purposes of restricted funds:

ADDER - Part of a multimillion pound investment and a system-wide programme that focus on co-ordinated law enforcement activity, alongside expanded diversionary programs using the criminal justice system to divert people away from offending.

50

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued) Purposes of restricted funds (continued):

Recovery Orientated Alcohol & Drugs Service (ROADS):

APPS/SMART - After Prison Prescribing Service (APPS) provides rapid prescribing for people released from prison. CHART, delivered by partner BrisDoc HealthCare Services provides a rapid prescribing service for people who are homeless or discharged from hospital;

Complex Needs - Delivery of a Consultant Psychiatrist-led range of pharmacological and psychological support to people with most complex needs, who are alcohol or drug dependent, sub-contracted to Avon and Wiltshire Partnership Mental Health Trust;

Early Engagement & Intervention delivering harm reduction services including needle and syringe programme, outreach, and work with non opiate users delivered by BDP and BBV interventions led by a nurse sub-contracted from Avon and Wiltshire Partnership Mental Health Trust (AWP) and a physical healthcare service delivered by a nurse sub-contracted from BrisDoc HealthCare Services; and

Substance Misuse Liaison delivering Opioid Substitution Treatment with GPs, community detox and alcohol detoxification.

Veterans - Donation from the Youngwood Trust enabling continuation of the Veteran Support Worker role from May 2020. After reviewing the veterans support organisations capacity to engage during and after the covid restrictions, it was agreed with the donor to pause this activity until a later date, not yet decided.

Purposes of designated funds:

50+ Get Back Out There - Funding made available by St Monica's Trust to Support Hub Partnership of which BDP is a member, to support our Get Back Out There 50+ Group.

ADDER (Addiction, Diversion, Disruption, Enforcement & Recovery)

Part of a multimillion pound investment and a system-wide programme that focus on co-ordinated law enforcement activity, alongside expanded diversionary programs using the criminal justice system to divert people away from offending.

Creative Communities - Small grant and donations supporting our Rising Voices Recovery Choir and Recovery Orchestra.

Dentaid Service - A Partnership between Bridon, Dentaid and BDP with the purpose of providing monthly pop-up dental health clinics for people who struggle to get their dental health needs met in the community due to homelessness, drug/alcohol use and complex needs.

51

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued)

Purposes of designated funds (continued):

Hepatitis C Engagement Worker - Partnership with Hep CU later, University Hospital Bristol Western and Gilead Research to fund a role that would engage and test people for Hepatitis C, working towards the WHO global strategy to reduce new infections.

Missing Link - Link worker role working with Next Link to decrease barriers for people suffering with domestic violence.

National Lottery - New Roots - To support BDP allotment and provide a growing project whilst being a specifically designed therapeutic, social space for support groups who use, or are in recovery from alcohol and drugs.

New Leaf Rapid - following a successful application through Vanguard (BNSSG Integrated Care Board), New Leaf Rapid has funding for 3 full time workers for 2 years. The pilot year is in Bristol and year 2 extended to South Gloucestershire and North Somerset. NLR works with Violence Reductions (Safer Options in Bristol), Education Inclusion Managers to harness a Drugs in School Pathway to reduce school exclusions for substance use or behaviours resulting from Children Affected By Substances trauma.

Safe Inhalation Pipe Prevention - Collaboration between London School of Hygiene and Tropical Medicine and BDP into research and evaluation on reducing health harms and increase service engagement for those who smoke crack cocaine in England.

Second Step Link Service- BDP employ and second a member of staff to the Second Step Link team. The Link Team supports people in Bristol who are street homeless or at imminent risk of homelessness, and who also experience severe emotional distress associated with a mental health problem.

Special Allocation Service (formerly known as Tackling Violence Service) - BDP is providing support to people with drug and alcohol dependence who are engaged with this primary health care service.

Street Intervention Service - Now funded by Rough Sleeping Drug and Alcohol Treatment Grant (RSDATG), initially funded by ROADS within Bristol City

Substance Misuse Liaison Connect - Project staff funded by Rough Sleeping Drug and Alcohol Treatment Grant (RSDATG) to support the delivery of OST to homeless service users and without a GP.

52

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued)

Purposes of designated funds (continued):

Targeted Youth Service - BDP delivers an element of this new service, sub-contracted by Creative Youth Network, focused on young alcohol and drug use, aged 11-19 years. The trustees have agreed to use General Funds for the shortfall of funding towards the performance of Targeted Youth Service.

Transformation Service - The transformation programme is a programme of work being undertaken by Bristol City Council to make improvements to the drug and alcohol treatment system and work towards the aims set out by the Government's strategy. This includes raising numbers of people in treatment, supporting more people to seek treatment for alcohol use and reducing drug related deaths.

Young Peoples Service - BDP has continued the targeted service offered previously under Targeted Youth Services, for young people who are using substances themselves and / or affected by parental substance misuse.

Youth Alcohol Drug Diversion - O ffers young people under 18 years arrested for first time possession of a substance controlled under the Misuse of Drugs Act, the opportunity to engage with a structured individual intervention with BDP as an alternative to a criminal justice disposal.

Designated funds less than £10,000 - These are funds received for specific services/projects ie. Investing in new technology to help BDP engage with the people we support and reduce the harms they face and support PRISM.

Transfers between funds - represent topping up of designated funds with general funds and the transfer of restricted funds to designated funds as agreed with funders.

53

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued)
Prior period comparative
Restricted funds
ADDER
Children's Youth Group (M32)
ROADS APPS/SMART
ROADS Complex Needs
Veterans
Total restricted funds
Unrestricted funds
Designated funds:
50+ Get Back Out There
50+ Winter Household Award
Creative Communities
Hep C Engagement Worker
Missing Link
National Lottery - New Roots
New Leaf
New Leaf Rapid
Safe Inhalation Pipe Prevention
Sub total designated funds
ROADS Substance Misuse Liaison
Street Intervention Service
ROADS Early Engagement & Intervention
Substance Misuse Liaison Connect		 At 1 April
2022
£
1,081
7,208
523
-
132,039
109,981
-
-
25,966
276,798
6,514
-
-
-
-
-
-
3,103
-
9,617		 Income
£
515,153
-
255,907
663,419
1,002,059
1,377,963
37,750
92,825
-
3,945,076
-
1,400
389
22,673
3,054
7,523
11,142
22,087
6,071
74,339		 £
(484,765)
(7,208)
(256,430)
(663,419)
(968,021)
(1,289,984)
(37,750)
(92,825)
-
(3,800,402)
(5,861)
(1,400)
(389)
(21,566)
(3,054)
(2,945)
(11,142)
(30,910)
(110)
(77,377)
Expenditure		 £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Transfers
between funds		 Gains /
(losses)
At 31 March
2023
£
£
-
31,469
-
-
-
-
-
-
-
166,077
-
197,960
-
-
-
-
-
25,966
-
421,472
-
653
-
-
-
-
-
1,107
-
-
-
4,578
-
-
-
(5,720)
-
5,961
-
6,579

54

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

16. Movement in funds (continued)
Prior period comparative (continued)
Unrestricted funds (continued)
Designated funds (continued):
Sub total brought forward
Special Allocation Service
Targeted Youth Service
Youth Alcohol Drug Diversion
Total designated funds
General funds
Total unrestricted funds
Total funds		 At 1 April
2022
£
9,617
-
-
-
9,617
3,698,075
3,707,692
3,984,490		 Income
£
74,339
7,982
142,676
3,182
228,179
65,296
293,475
4,238,551		 £
(77,377)
(7,982)
(159,526)
(3,182)
(248,067)
(147,453)
(395,520)
(4,195,922)
Expenditure		 £
-
-
16,850
-
16,850
(16,850)
-
-
Transfers
between funds		 Gains /
(losses)
£
-
-
-
-
-
-
-
-		 At 31 March
2023
£
6,579
-
-
-
6,579
3,599,068
3,605,647
4,027,119

17. Called up share capital

There is no share capital as the company is limited by guarantee. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity as stated in the Memorandum and Articles of Association.

18. Related party transactions

Michael Lea, Trustee, was also a Trustee of Bristol Old Vic and Theatre Royal Trust Limited (resigned 12 July 2022) with whom BDP receive funds to deliver the ROADS Early Engagement & Intervention Service. During the prior year the charity made sales of £2,820 to Bristol Old Vic and Theatre Royal Trust Limited, of which £600 was included in debtors at year end.

55

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2024

17. Called up share capital

There is no share capital as the company is limited by guarantee. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity as stated in the Memorandum and Articles of Association.

18. Related party transactions

There were no related party transactions in the current year. In the prior year BDP received £2,820 of income from Bristol Old Vic and Theatre Royal Trust which was a related party by virtue of having a trustee in common.

56